and hematologic_diseases. Several of these diseases are among the leading causes of disability and death;
http://www.nlm.nih.gov/databases/alerts/sickle_cell.html
Drug Treatment for Sickle_cell Anemia Clinical Alert:
Drug Treatment for Sickle_cell Anemia National Heart, Lung,
and Blood Institute (NHLBI) today announced a drug treatment for sickle_cell anemia.
Hydroxyurea has_been_used primarily to treat myeloproliferative_disorders such_as polycythemia_vera.
Although the exact mechanism of action in sickle_cell anemia is_understood not completely,
and Drug Administration to treat sickle_cell anemia although physicians can prescribe it for that purpose.
Hydroxyurea may_not be appropriate for all patients with sickle_cell anemia,
These findings are the results of data analyzed from the Multicenter Study of Hydroxyurea in Sickle_cell Anemia (MSH),
which reduces the frequency of painful episodes or crises in patients with sickle_cell anemia.
Recurrent painful episodes are the most disabling feature of sickle_cell anemia, interfering with education, vocational_training, job retention and psychosocial development.
a life-threatening complication of sickle_cell anemia characterized by chest_pain,
which up until this trial had primarily been_used to treat myeloproliferative_disorders such_as polycythemia_vera
. Although the exact mechanism of action in sickle_cell anemia is_understood not completely,
which are the hallmarks of sickle_cell anemia. Increased levels of fetal hemoglobin inside sickle red_blood_cells may prevent the cells from becoming rigid,
thereby preventing vaso-occlusion. These findings are the results of data analyzed from the Multicenter Study of Hydroxyurea in Sickle_cell Anemia (MSH),
and the Maryland Medical Research Institute (Dr. Michael Terrin) enrolled 299 adult sickle_cell anemia (Hb SS) patients
or=7. 0 gm/dl (pre-enrollment) to 4. 5-5. 0 if reticulocytes Hydroxyurea may_not be appropriate for all patients with sickle_cell anemia,
each sickle_cell anemia patient must be_evaluated carefully before hydroxyurea therapy is_begun,
as_long_as the patient continues to take the prescribed dose. Hydroxyurea is_used for treatment of polycythemia_vera,
a disease in which too many red_blood_cells are_produced. In an open label study of polycythemia_vera now entering its 15th year,
and other health_problems. Safety of this agent for children with sickle_cell anemia must be_determined. Physicians can prescribe hydroxyurea for the treatment of sickle_cell anemia in their patients,
http://www.ncbi.nlm.nih.gov/genome/guide/HsChr1.shtml
Some diseases associated with chromosome 1 mutations Chediak-higashi_syndrome Charcot-Marie-Tooth Neuropathy-2a Ductal Breast_cancer Gaucher_disease Usher Syndrome,
http://www.ncbi.nlm.nih.gov/genome/guide/HsChr19.shtml
and Sutherland 6 Some diseases associated with chromosome 19 mutations Acute T_cell Leukemia Diamond-Blackfan Anemia Myotonic_dystrophy See OMIM
http://www.nlm.nih.gov/medlineplus/newsbydate.html
Help Predict Lymphoma Survival (Reuters Health) Italy:
http://www.ncbi.nlm.nih.gov/disease/Metabolism.html
Obesity Paroxysmal nocturnal hemoglobinuria Phenylketonuria Refsum_disease Tangier_disease Tay-sachs_disease METABOLISM is the means by
http://www.ncbi.nlm.nih.gov/disease/Transporters.html
syndrome Polycystic_kidney_disease Sickle_cell anemia Wilson's disease Zellweger_syndrome TRANSPORTERS, CHANNELS AND PUMPS that reside in cell_membranes are key to maintaining the right balance
http://www.ncbi.nlm.nih.gov/sky/protocol.cgi
. It incorporates the new classifications for lymphomas and leukemias (Harris et_al.
http://www.nlm.nih.gov/databases/alerts/rectal_cancer.html
However, after chronic administration, this drug has_been_associated with a 12-fold increased risk for secondary leukemia or preleukemia (7) as_well_as with chronic renal toxicity.
Severe thrombocytopenia was_seen only in patients receiving methyl-CCNU,
Med 315: 1294,1986 BOICE JD, GREEN MH, et_al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU.
http://www.nlm.nih.gov/databases/alerts/sickle97.html
Periodic Transfusions Lower Stroke Risk in Children with Sickle_cell Anemia Clinical Alert:
Periodic Transfusions Lower Stroke Risk in Children with Sickle_cell Anemia National Heart, Lung,
and Blood Institute today announced that periodic red_blood_cell transfusions in children with sickle_cell anemia has_been found to reduce the rate of stroke in those patients.
The study--the Stroke Prevention Trial in Sickle_cell Anemia (STOP)--compared stroke rates in 63 children who received periodic transfusions with 67 children who were getting standard supportive care.
The STOP study also confirmed that transcranial doppler screening can be_used to identify children with sickle_cell anemia who are at high risk for a first-time stroke.
Before screening children with sickle_cell anemia for stroke risk,
and Blood Institute (NHLBI) announced today a treatment that reduces the rate of stroke (cerebral_infarction) in children with sickle_cell anemia. Strokes occur in approximately 10%of children
with sickle_cell anemia. These events can be very debilitating, leading to physical and neuropsychological impairment
Anemia (STOP) proposed to reduce first_time stroke in children with sickle_cell anemia
and their parents. The STOP Trial confirmed that TCD can identify children with sickle_cell anemia at high risk for first_time stroke
and unnecessarily transfused. It is_recommended that centers that wish to start screening children with sickle_cell anemia for stroke risk do studies to compare their current equipment with STOP Trial
and the care of the child with sickle_cell anemia. For more information on the STOP Trial, contact Dr. Robert Adams at 706-721-4670 or the Sickle_cell
and for screening children with sickle_cell anemia to ascertain stroke risk
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=80
potential for defining predictive markers in sarcoidosis Ulrike Seitzer, Johannes Gerdes,
http://www.nlm.nih.gov/databases/alerts/amd.html
. Participants in the two groups that took zinc also reported anemia at a slightly higher rate;
http://www.ncbi.nlm.nih.gov:80/entrez/journals/active_providers.html
for X-Linked agammaglobulinemia (BTK) Bugwood Network (University of Georgia)( Bugwood) Butterfly Net International (BNI
http://www.ncbi.nlm.nih.gov/entrez/Omim/allresources.html
The BTKBASE mutation registry for X-Linked agammaglobulinemia The Cystic_fibrosis Mutation Database The Emery-Dreifuss Muscular_dystrophy Mutation
http://www.ncbi.nlm.nih.gov:80/entrez/journals/loprovlink.html
OMIM BTKBASE mutation registry for X-Linked agammaglobulinemia (BTK:
http://www.nih.gov/news/pr/jun2002/nci-19.htm
NIH News Release--Gene Expression Profiles Predict Survival of Lymphoma Patients After Chemotherapy--6/19/2002 NATIONAL_INSTITUTES_OF_HEALTH National
NCI Press Office (301) 496-6641 Gene Expression Profiles Predict Survival of Lymphoma Patients After Chemotherapy Patterns of genes
whether patients with diffuse large B_cell lymphoma (DLBCL) are likely to be_cured by chemotherapy,
*Researchers analyzed thousands of genes in lymphoma biopsy samples from patients with DLBCL and determined that the activity of as few as 17 genes could be_used to predict patients'response
DLBCL is the most common type of non-Hodgkin's lymphoma in adults.
"For half of the patients with diffuse large B_cell lymphoma, conventional chemotherapy appears to be a reasonable option,
lymphoma cells have_activated this pathway,
"This research was_sponsored by NCI as part_of the Lymphoma/Leukemia Molecular Profiling Project and the NCI Director's Challenge.
The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large B_cell Lymphoma.